Memantin Abz (Memantine Hydrochloride)

Memantin Abz acts on the glutamatergic pathway implicated in neurodegeneration, primarily used in Alzheimer’s disease management.

• Alzheimer’s disease: improves cognitive function and daily living activities in moderate to severe stages.
• Vascular dementia: (not an approved indication, therefore omitted).
• Parkinson’s disease dementia: (not an approved indication, therefore omitted).

• Memantine hydrochloride binds to the NMDA (N‑methyl‑D‑aspartate) receptor at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By reducing excessive calcium influx through the receptor channel, it limits excitotoxic neuronal injury while preserving normal synaptic transmission, thereby supporting neuronal survival in Alzheimer’s disease.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: transient cranial discomfort.
• Constipation: reduced bowel movements.
• Fatigue: feeling unusually tired.
• Insomnia: difficulty initiating or maintaining sleep.
• Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Hypertension: elevated blood pressure requiring monitoring.
• Cardiac arrhythmia: irregular heart rhythm.
• Hepatic injury: signs of liver dysfunction.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Stevens‑Johnson syndrome: rare severe skin reaction.

Memantin Abz should be used with caution in patients with the following considerations:

• Renal impairment: adjust therapy based on renal function.
• Hepatic impairment: monitor liver enzymes regularly.
• History of seizures: assess risk versus benefit.
• Cardiovascular disease: observe blood pressure and heart rate.
• Concomitant NMDA antagonists: avoid combined use to prevent additive effects.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantin Abz may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid)

• Amantadine or other NMDA antagonists: may increase neurotoxicity.
• CNS depressants (e.g., benzodiazepines): can enhance sedation.
• Drugs that lower seizure threshold: may increase seizure risk.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may exacerbate cognitive side effects.
• Antihypertensive medications: possible additive blood pressure reduction.
• Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome.
• Antipsychotics: observe for increased dizziness or confusion.
• Diuretics: watch for electrolyte imbalances.